Avalo Therapeutics, Inc. (AVTX) has disclosed a new risk, in the Regulation category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An external reviewer notes that Avalo Therapeutics, Inc. directs investors to carefully weigh the risk factors detailed in Part I of its Form 10‑Q when assessing the company’s outlook. This emphasis suggests that previously disclosed risks remain highly relevant and could materially affect Avalo’s operations, financial condition, and future prospects.
The average AVTX stock price target is $46.89, implying 136.22% upside potential.
To learn more about Avalo Therapeutics, Inc.’s risk factors, click here.